Federico Fusco

Federico Fusco

Auto-generated profile, based on publicly available information

Federico Fusco

Institute of Pathology, School of Medicine and Health, German Cancer Consortium, Technical University of Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AMArtuer Manukyan
Artuer Manukyan
KPKristin Peters
Kristin Peters
HRHelena Radbruch
Helena Radbruch
FFFederico Fusco
Federico Fusco
FGFelicitas Geserick
Felicitas Geserick
TRTorben Redmer
Torben Redmer
Summary: The cellular composition of the tumor ecosystem is a critical determinant of therapeutic responsiveness to immune checkpoint inhibitors (ICi) and BRAF inhibitors (BRAFi). However, the specific compositional dynamics that drive the subsequent progression of melanoma brain metastases (MBMs) remain poorly understood. Here, we performed single cell-resolved spatial transcriptomics profiling of multiple tissue cores (n=47) of distinct solitary and concordant multiple MBM (n=8), CNS tissue (n=7) and whole sections including one matched primary (n=4) of MBMs across various developmental stages and therapeutic regimens. Our approach uncovered both shared and distinct evolutionary patterns of MBM progression, revealing pronounced cellular and spatial heterogeneity, and identifying key tumor subsets characterized by MET or NGFR expression. Notably, spatial profiling of tumors progressing under ICi or BRAFi therapy identified a population of BZW2 + tumor cells that promotes an immunosuppressive microenvironment, thereby impeding immune cell infiltration and intratumoral dispersion. Elevated BZW2 expression was associated with ICi resistance and inversely correlated with the antigen transporter TAP1 and the activation of interferon/STAT1 signaling. Spatially aware automated profiling of immune-enriched niches distinguished “hot” niches—characterized by tumor expression of TAP1, PD-L2 and HLA-DRA—from “cold” zones, which were characterized by high levels of BZW2 and the transcriptional regulator SOX4. This translational suppressor co-localized with the clinically targetable MET receptor in a subset of tumor cells exhibiting distinct immune evasion features. Finally, multiplex imaging based on MACSima showed that, across all tumors, only 0.1% of CD8A + T cells were in an activated state. In summary, we provide insights into the single-cell and spatially resolved landscapes of MBM, identifying BZW2/SOX4 and TAP1 as potential determinants of ICi response.

24 March 2026 in Laboratory Investigation
Verified
Journal Article
Open access
FFFederico Fusco
Federico Fusco
JWJohannes Weigel
Johannes Weigel
MSMarius Schliemann
Marius Schliemann
ASAnnika Schneider
Annika Schneider
YZYuxiang Zhou
Yuxiang Zhou
PKPeer-Hendrik Kuhn
Peer-Hendrik Kuhn
Immune checkpoint inhibitors (ICIs) have markedly improved outcomes in malignant melanoma, yet accessible, tissue-based predictive biomarkers of response remain limited. PD-L1 expression, which remains widely used, offers some prognostic value but performs poorly at low expression levels. We performed liquid chromatography-mass spectrometry proteomic profiling on 185 melanoma samples, including 52 pretreatment samples from ICI responders and nonresponders. Differential expression and pathway analyses identified a 73-protein immune activation signature correlating with ICI response. Within this immune context, SH2D1A (SAP), a regulator of T- and natural killer-cell cytotoxicity, emerged as a top candidate biomarker. Internal immunohistochemical validation confirmed its strong predictive accuracy (area under the receiver operating characteristic curve: 0.93; sensitivity: 88%; specificity: 91%) in distinguishing responders from nonresponders, outperforming PD-L1, CD3, and CD8. Notably, SH2D1A retained its predictive power in PD-L1-low tumors (combined positive score < 10), suggesting clinical use in which the current markers fall short. Independent validation in an external tissue microarray cohort revealed attenuated predictive performance, likely reflecting the impact of intratumoral heterogeneity, as further suggested by whole-slide validation. Nevertheless, SH2D1A remained significantly enriched in tumors that responded to ICIs and was associated with improved survival outcomes, outperforming CD3, CD8, and PD-L1. In conclusion, these results suggest that SH2D1A provides information beyond established immune infiltration- and exhaustion-related markers, supporting further investigation of its potential role in biomarker-guided prediction of ICI response in melanoma.

24 January 2026 in Pathology
Verified
Journal Article
Open access
FFFederico Fusco
Federico Fusco
MWMaria Walker
Maria Walker
NPNicole Pfarr
Nicole Pfarr
KSKatja Specht
Katja Specht
CBChristine Bollwein
Christine Bollwein
CMCarolin Mogler
Carolin Mogler
Nodular fasciitis is a benign, rapidly growing myofibroblastic neoplasm that can mimic sarcomas, typically posing a diagnostic challenge. This retrospective, single-institution series presents 29 cases of nodular fasciitis collected over 9 years. Two-thirds of the cases (19/29) presented as non-specific soft-tissue lesions that did not initially raise suspicion for nodular fasciitis and/or showed alarming histological features. Among these, five exhibited unusual localisations, including three deep-seated, subfascial lesions (two intraneural) and two juxta-articular lesions. Histopathology was consistent with nodular fasciitis in all cases. Fluorescence in situ hybridisation (FISH) and next-generation sequencing (NGS) confirmed the diagnosis: USP6 rearrangements were identified in all 19 non-specific cases, with FISH detecting alterations in 15 cases (83.3% of those tested). Although useful, FISH posed interpretive challenges; NGS resolved ambiguous cases and identified three rare USP6 fusion partners (MIR22HG, CTNNB1, and SRSF3), which showed distinctive cellular histomorphology despite longer pre-operative age, two of which appeared in atypical locations. This series offers an integrated clinicopathological and molecular overview of diagnostically challenging nodular fasciitis, emphasising the importance of including it in the differential diagnosis of mesenchymal tumours in both superficial and deep sites. We believe this series contributes to the understanding of USP6-associated neoplasia and will aid pathologists in recognising nodular fasciitis in challenging settings, enhance diagnostic confidence, and support targeted use of advanced molecular techniques.